The evolving treatment of diabetic retinopathy
SE Mansour, DJ Browning, K Wong… - Clinical …, 2020 - Taylor & Francis
Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …
Anti‐vascular endothelial growth factor for diabetic macular oedema
G Virgili, M Parravano, F Menchini… - Cochrane Database of …, 2014 - cochranelibrary.com
Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …
Diabetic retinopathy preferred practice pattern®
Background: Diabetic retinopathy is a leading cause of visual impairment in working-age
adults worldwide. Duration of diabetes is a major risk factor associated with the development …
adults worldwide. Duration of diabetes is a major risk factor associated with the development …
Deep learning algorithm predicts diabetic retinopathy progression in individual patients
The global burden of diabetic retinopathy (DR) continues to worsen and DR remains a
leading cause of vision loss worldwide. Here, we describe an algorithm to predict DR …
leading cause of vision loss worldwide. Here, we describe an algorithm to predict DR …
Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial
JG Gross, AR Glassman, LM Jampol, S Inusah… - Jama, 2015 - jamanetwork.com
Importance Panretinal photocoagulation (PRP) is the standard treatment for reducing severe
visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina …
visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina …
[HTML][HTML] Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE
DM Brown, QD Nguyen, DM Marcus, DS Boyer, S Patel… - Ophthalmology, 2013 - Elsevier
Purpose To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330),
trials of ranibizumab in diabetic macular edema (DME). Design Phase III, randomized …
trials of ranibizumab in diabetic macular edema (DME). Design Phase III, randomized …
Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy
OBJECTIVE To evaluate the association between initial diabetic retinopathy (DR)
severity/risk of blindness in patients with newly diagnosed DR/good vision in the US …
severity/risk of blindness in patients with newly diagnosed DR/good vision in the US …
Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases
PA Campochiaro, A Akhlaq - Progress in retinal and eye research, 2021 - Elsevier
Neovascular age-related macular degeneration (NVAMD) is the most prevalent choroidal
vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the …
vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the …
Systemic safety of prolonged monthly anti–vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis
RL Avery, GM Gordon - JAMA ophthalmology, 2016 - jamanetwork.com
Importance Anti–vascular endothelial growth factor (VEGF) therapy is commonly used to
treat numerous retinal conditions and appears safe, yet controversy remains regarding …
treat numerous retinal conditions and appears safe, yet controversy remains regarding …
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
R Simo, C Hernandez - Progress in Retinal and eye Research, 2015 - Elsevier
Diabetic retinopathy remains as a leading cause of blindness in developed countries.
Current treatments target late stages of DR when vision has already been significantly …
Current treatments target late stages of DR when vision has already been significantly …